BioNTech SE

As of June 30, 2026, BioNTech SE Sponsored ADR carries a market capitalization of 398.54B, placing it among publicly traded companies globally. Its enterprise value stands at 109.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioNTech SE Sponsored ADR's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, BioNTech SE Sponsored ADR has 251.20M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 7.42, and the price-to-book ratio stands at 1.12.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 109.85B versus a market cap of 398.54B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioNTech SE Sponsored ADR maintains a current ratio of 7.85, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.78, indicating elevated leverage, while an interest coverage ratio of -175.85 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioNTech SE Sponsored ADR posted a negative return on equity (ROE) of -9.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.03, reflecting losses generated across the asset base. The company generates approximately 7.01M in revenue per employee across its workforce of 7,548.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.92 indicates how many times BioNTech SE Sponsored ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioNTech SE Sponsored ADR recorded 1.14B in income tax expense. The company reported a pretax loss of -32.53B and -33.66B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, BioNTech SE Sponsored ADR's stock has declined approximately 12.30% over the past 52 weeks. The 50-day moving average sits at 1,679.85, while the 200-day moving average is 1,940.08.

Over the twelve months ended June 30, 2026, BioNTech SE Sponsored ADR generated 52.90B in revenue and converted that into -33.66B in net income, yielding earnings per share of -136.04. EBITDA reached -26.33B, while operating income came in at -24.68B.

As of June 30, 2026, BioNTech SE Sponsored ADR holds 295.00B in cash and equivalents against 6.31B in total debt, resulting in a net debt position of -188.13B. Total book value stands at 354.45B, with working capital of 266.44B providing operational flexibility.

BioNTech SE Sponsored ADR produced 13.57B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.69B in capital expenditures, free cash flow totaled 8.88B - equivalent to 35.87 per share.

Over the twelve months ended June 30, 2026, BioNTech SE Sponsored ADR posted a gross margin of 75.47, reflecting its pricing power and cost economics. The operating margin of -46.66 and net profit margin of -63.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.26, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.54, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioNTech SE Sponsored ADR shareholders.

As of June 30, 2026, BioNTech SE Sponsored ADR has an Altman Z-Score of 6.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.